- Home
- JFU vs ANL Comparison
JFU vs ANL Comparison
Compare JFU & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | JFU | ANL |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | China | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.2M | 62.0M |
| IPO Year | 2019 | 2023 |
Fundamental Metrics
Financial Performance| Metric | JFU | ANL |
|---|---|---|
| Price | $5.95 | $1.95 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 9.3K | ★ 1.3M |
| Earning Date | 12-09-2022 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3110.57 | N/A |
| EPS | ★ 3.04 | N/A |
| Revenue | ★ $44,573,690.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.94 | ★ N/A |
| Revenue Growth | ★ 8.19 | N/A |
| 52 Week Low | $1.01 | $0.88 |
| 52 Week High | $9.48 | $2.75 |
Technical Indicators
Market Signals| Indicator | JFU | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 45.34 | 67.92 |
| Support Level | $5.39 | $1.63 |
| Resistance Level | $6.10 | $1.93 |
| Average True Range (ATR) | 0.70 | 0.15 |
| MACD | -0.16 | 0.04 |
| Stochastic Oscillator | 32.65 | 89.36 |
Price Performance
Historical ComparisonAbout JFU 9F Inc.
9F Inc is a financial account platform integrating and personalizing financial services in China. It provides a range of financial products and services across online lending, wealth management, and payment facilitation, all integrated under a single digital financial account. The company's operations are organized into Material segments, consisting of E-commerce services, technology Empowerment service and Wealth Management services, of which it derives maximum revenue from technology Empowerment service. All its revenues are generated from the People's Republic of China.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.